A phase I, pharmacokinetic and pharmacodynamic study of panobinostat, an HDAC inhibitor, combined with erlotinib in patients with advanced aerodigestive tract tumors

Ítems similars

• Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer
  per: Haura, Eric B., et al.
  Publicat: (2010)
• Randomized International Phase III Trial of ERCC1 and RRM1 Expression–Based Chemotherapy Versus Gemcitabine/Carboplatin in Advanced Non–Small-Cell Lung Cancer
  per: Bepler, Gerold, et al.
  Publicat: (2013)
• Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance
  per: Creelan, Ben C., et al.
  Publicat: (2019)
• Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma
  per: Creelan, Ben C., et al.
  Publicat: (2013)
• Phase II Randomized Study of Enzastaurin (LY317615) for Lung Cancer Prevention in Former Smokers
  per: Gray, Jhanelle E., et al.
  Publicat: (2012)